These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 34456098)

  • 1. Inflammation and ischemic heart disease: The next therapeutic target?
    Vilela EM; Fontes-Carvalho R
    Rev Port Cardiol (Engl Ed); 2021 Aug; ():. PubMed ID: 34456098
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inflammation and ischemic heart disease: The next therapeutic target?
    Vilela EM; Fontes-Carvalho R
    Rev Port Cardiol (Engl Ed); 2021 Oct; 40(10):785-796. PubMed ID: 34857118
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Why Colchicine Should Be Considered for Secondary Prevention of Atherosclerosis: An Overview.
    Nidorf SM; Thompson PL
    Clin Ther; 2019 Jan; 41(1):41-48. PubMed ID: 30591286
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Anti-inflammatory therapy in cardiovascular disease; from hypothesis to future guideline?].
    Hoogeveen RM; Stroes ESG; Cornel JH
    Ned Tijdschr Geneeskd; 2020 Oct; 164():. PubMed ID: 33201620
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-inflammatory therapy in ischaemic heart disease: from canakinumab to colchicine.
    Andreotti F; Maggioni AP; Campeggi A; Iervolino A; Scambia G; Massetti M
    Eur Heart J Suppl; 2021 Oct; 23(Suppl E):E13-E18. PubMed ID: 34650351
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lessons learned from large Cardiovascular Outcome Trials targeting inflammation in cardiovascular disease (CANTOS, CIRT, COLCOT and LoDoCo2).
    Samuel M; Tardif JC
    Future Cardiol; 2021 May; 17(3):411-414. PubMed ID: 33687270
    [No Abstract]   [Full Text] [Related]  

  • 7. Targeting Inflammation After Myocardial Infarction.
    Mahtta D; Sudhakar D; Koneru S; Silva GV; Alam M; Virani SS; Jneid H
    Curr Cardiol Rep; 2020 Aug; 22(10):110. PubMed ID: 32770365
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting Inflammation to Reduce Residual Cardiovascular Risk.
    Ajala ON; Everett BM
    Curr Atheroscler Rep; 2020 Sep; 22(11):66. PubMed ID: 32880743
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An Update on Inflammation in Atherosclerosis: How to Effectively Treat Residual Risk.
    Mohammadnia N; Opstal TSJ; El Messaoudi S; Bax WA; Cornel JH
    Clin Ther; 2023 Nov; 45(11):1055-1059. PubMed ID: 37716836
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inflammation and cardiovascular diseases: lessons from seminal clinical trials.
    Liberale L; Montecucco F; Schwarz L; Lüscher TF; Camici GG
    Cardiovasc Res; 2021 Jan; 117(2):411-422. PubMed ID: 32666079
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Closing the loop on inflammation and atherothrombosis: why perform the CIRT and CANTOS trials?
    Ridker PM
    Trans Am Clin Climatol Assoc; 2013; 124():174-90. PubMed ID: 23874021
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Update on the Inflammatory Hypothesis of Coronary Artery Disease.
    Boland J; Long C
    Curr Cardiol Rep; 2021 Jan; 23(2):6. PubMed ID: 33409720
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Atherothrombosis Prevention and Treatment with Anti-interleukin-1 Agents.
    Biondi-Zoccai G; Garmendia CM; Abbate A; Giordano A; Frati G; Sciarretta S; Antonazzo B; Versaci F
    Curr Atheroscler Rep; 2020 Jan; 22(1):4. PubMed ID: 31932973
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inflammation May be the Future of Cardiovascular Risk Reduction: Does Colchicine have a Current Indication?
    Whayne TF
    Am J Cardiovasc Drugs; 2021 Jan; 21(1):1-10. PubMed ID: 32356107
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Colchicine in the Management of Acute and Chronic Coronary Artery Disease.
    Bouabdallaoui N; Tardif JC
    Curr Cardiol Rep; 2021 Jul; 23(9):120. PubMed ID: 34269908
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Colchicine for the treatment of coronary artery disease.
    Aimo A; Pascual-Figal DA; Barison A; Cediel G; Vicente ÁH; Saccaro LF; Emdin M; Bayes-Genis A
    Trends Cardiovasc Med; 2021 Nov; 31(8):497-504. PubMed ID: 33096241
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Role of Suppressing Inflammation in the Treatment of Atherosclerotic Cardiovascular Disease.
    Roman YM; Hernandez AV; White CM
    Ann Pharmacother; 2020 Oct; 54(10):1021-1029. PubMed ID: 32425120
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Moving beyond JUPITER: will inhibiting inflammation reduce vascular event rates?
    Ridker PM
    Curr Atheroscler Rep; 2013 Jan; 15(1):295. PubMed ID: 23225175
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS).
    Ridker PM; Thuren T; Zalewski A; Libby P
    Am Heart J; 2011 Oct; 162(4):597-605. PubMed ID: 21982649
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Residual inflammatory risk associated with interleukin-18 and interleukin-6 after successful interleukin-1β inhibition with canakinumab: further rationale for the development of targeted anti-cytokine therapies for the treatment of atherothrombosis.
    Ridker PM; MacFadyen JG; Thuren T; Libby P
    Eur Heart J; 2020 Jun; 41(23):2153-2163. PubMed ID: 31504417
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.